2021
Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy
Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. American Journal Of Clinical Pathology 2021, 156: 214-228. PMID: 33555016, DOI: 10.1093/ajcp/aqaa217.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseCD8/FOXP3 ratioBiopsy specimensCPI patientsPD-1CD68 scoreFOXP3 ratioBowel diseasePD-L1Antibody-treated patientsCheckpoint inhibitor colitisPD-L1 groupInitial biopsy specimensPD-L1 expressionImmune cell reactionsColonic biopsy specimensDrug-specific differencesIBD groupCheckpoint inhibitorsChronicity scoreActivity scoreImmune phenotypeTherapeutic responseColitisShared pathophysiology
2020
Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors.
Perdigoto AL, Tran T, Patel N, Clark P, Patell K, Stamatouli AM, Reddy V, Clune J, Herold KC, Robert ME, Kluger HM. Elective Colectomy in a Patient with Active Ulcerative Colitis and Metastatic Melanoma Enabling Successful Treatment with Immune Checkpoint Inhibitors. Clinical Oncology Case Reports 2020, 3 PMID: 33778814, PMCID: PMC7993656.Peer-Reviewed Original ResearchCheckpoint inhibitor therapyElective colectomyUlcerative colitisInhibitor therapyMetastatic melanomaImmune-related adverse eventsExcellent tumor responseImmune checkpoint inhibitorsSevere ulcerative colitisActive ulcerative colitisCheckpoint inhibitor immunotherapyCheckpoint inhibitor treatmentInflammatory bowel diseaseEffective treatment optionBenefits of treatmentImmune system activationTumor cell destructionCheckpoint inhibitorsAdvanced malignanciesAdverse eventsSelect patientsBowel diseaseAutoimmune diseasesTreatment optionsTumor response
1996
Rectal afferent function in patients with inflammatory and functional intestinal disorders
Bernstein C, Niazi N, Robert M, Mertz H, Kodner A, Munakata J, Naliboff B, Mayer E. Rectal afferent function in patients with inflammatory and functional intestinal disorders. Pain 1996, 66: 151-161. PMID: 8880836, DOI: 10.1016/0304-3959(96)03062-x.Peer-Reviewed Original ResearchConceptsIrritable bowel syndromeInflammatory bowel diseaseDiarrhea-predominant irritable bowel syndromeViscerosomatic referral patternCrohn's disease patientsIBS patientsDisease patientsCrohn's diseaseMale patientsReferral patternsAfferent pathwaysReflex responsesHealthy male control subjectsTissue irritationAutonomic reflex responsesChronic ileal inflammationLower distension pressuresRapid phasic distensionDorsal horn neuronsVisceral afferent pathwaysIleal Crohn's diseaseFunctional intestinal disordersMale control subjectsSkin conductance responsesBulbospinal inhibition